Relx (NYSE:RELX) Rating Lowered to “Hold” at StockNews.com

Relx (NYSE:RELX) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Separately, Redburn Atlantic began coverage on Relx in a research report on Wednesday, January 8th. They set a “buy” rating on the stock.

Relx Price Performance

Shares of RELX opened at $49.29 on Friday. The business’s 50 day moving average is $48.09 and its two-hundred day moving average is $47.27. Relx has a 52-week low of $40.25 and a 52-week high of $51.99. The company has a quick ratio of 0.47, a current ratio of 0.52 and a debt-to-equity ratio of 1.46.

Institutional Investors Weigh In On Relx

Institutional investors and hedge funds have recently made changes to their positions in the company. CENTRAL TRUST Co raised its position in shares of Relx by 1,290.2% during the 4th quarter. CENTRAL TRUST Co now owns 570 shares of the technology company’s stock valued at $26,000 after acquiring an additional 529 shares in the last quarter. Versant Capital Management Inc acquired a new stake in Relx in the fourth quarter worth $31,000. Transce3nd LLC acquired a new stake in Relx in the fourth quarter worth $40,000. Sierra Ocean LLC acquired a new stake in Relx in the fourth quarter worth $43,000. Finally, Brown Brothers Harriman & Co. increased its position in Relx by 218.5% in the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company’s stock worth $44,000 after buying an additional 662 shares during the period. 15.02% of the stock is owned by institutional investors and hedge funds.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.